NYSE:DOCS 6 December 2025

Doximity (DOCS) Stock Hits New 52‑Week Low After Earnings Beat – Latest News, Forecasts and Outlook as of December 5, 2025

Doximity shares fell over 10% to close at $45.93 on December 5, 2025, hitting a new 52-week low despite reporting Q2 revenue of $168–169 million and non-GAAP EPS of $0.45, both above estimates. The stock now trades about 46% below its February high. Management raised full-year revenue guidance, while analysts maintain a consensus “Buy” rating with an average target near $68.

6 December 2025

Earnings Reports·Financial Forecasts·NYSE:DOCS·Stock Market

Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

The S&P 500 closed at 6,870.40, up 0.19% Friday, while Bitcoin fell 3% to just under $89,300. Parsons plunged 21% after losing a key FAA contract; other steep U.S. decliners included Adaptive Biotechnologies, SentinelOne, and several Brazilian financials. Brazil’s Bovespa index dropped 4% after Jair Bolsonaro endorsed his son for president, sending the real down 3%.

6 December 2025

NASDAQ:ADPT·NASDAQ:INTR·NASDAQ:NNNN·NASDAQ:PSKY·NASDAQ:XP·NYSE:AGX·NYSE:CSAN·NYSE:DOCS·NYSE:PSN·NYSE:S·Stock Market

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).